Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

TCR2 Therapeutics Inc.

www.tcr2.com

Latest From TCR2 Therapeutics Inc.

IPO Update: Gottlieb’s Resignation Pulls Down Five Of Eight Newly Public Biopharmas

There have been eight US biopharma IPOs in 2019, but only three are trading above their launch price – a big change from just three days ago.

Financing Business Strategies

Finance Watch: Anchiano, TCR2, Hoth And Stealth Make Seven US Biopharma IPOs For 2019

Public Company Edition: Four more IPOs in the US bring the year's total to seven – all in February. Also, Agenus launched its digital security offering, MacroGenics leads recent follow-on offerings and four companies reveal new job cuts.

Financing Business Strategies

MPM Raises $400m To Build Early-Stage Biotechs

The venture capitalist builds biotechs from scratch and with this latest fund, MPM is looking to add to its sector-leading record of 49 FDA-approved drugs and over 100 IPOs and acquisitions.

Financing ImmunoOncology

Finance Watch: Gossamer, Alector And Harpoon Launch First Biopharma IPOs Of 2019

Public Company Edition: Grossing $276m, Gossamer would have been the third-largest biopharma IPO in the US if it had launched last year. Also, recent public company financings include debt and follow-on offerings; and two more firms cut jobs – Capricor and Seres.

Financing Business Strategies
See All

Company Information

  • Industry
  • Biotechnology
    • Gene Therapy, Cell Therapy
  • Pharmaceuticals
    • Vaccines
  • Therapeutic Areas
  • Cancer
  • Alias(es)
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Company Type
  • Start-Up
  • Parent & Subsidiaries
  • TCR2 Therapeutics Inc.
  • Senior Management
  • Garry Menzel, PhD, Pres. & CEO
    Ian Somaiya, CFO
    Robert Hofmeister, PhD, CSO
    Alfonso Quintas Cardama, MD, CMO
  • Contact Info
  • TCR2 Therapeutics Inc.
    Phone: (617) 949-5200
    100 Binney St.
    Ste. 710
    Cambridge, MA 02142
    USA
Advertisement
Advertisement
UsernamePublicRestriction

Register